Vera Therapeutics (VERA) Cash from Investing Activities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Cash from Investing Activities data on file, last reported at -$137.8 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 999.76% year-over-year to -$137.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.2 million (up 121.61% YoY) and the FY2025 annual result came in at $194.3 million, up 145.71% from the prior year.
• Cash from Investing Activities slipped to -$137.8 million in Q1 2026, from $80.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $80.7 million in Q4 2025 to a low of -$221.4 million in Q4 2024.
• A 5-year average of -$28.1 million and a median of $12.2 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 5388.19% — and 2023, when it jumped 765.08%.
• Tracing VERA's Cash from Investing Activities over 5 years: stood at $13.4 million in 2022, then surged by 38.1% to $18.6 million in 2023, then slumped by 1293.05% to -$221.4 million in 2024, then surged by 136.44% to $80.7 million in 2025, then slumped by 270.85% to -$137.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$137.8 million (Q1 2026), $80.7 million (Q4 2025), and $69.8 million (Q3 2025), per Business Quant data.